Vildagliptin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Vildagliptin: From Type 2 Diabetes to Classic Stiff Person Syndrome
One-Sentence Summary
Vildagliptin is a DPP-4 inhibitor used to manage type 2 diabetes (confirmed only via literature captured in this evidence pack — no official SAHPRA indication text is on file). The TxGNN model’s top-ranked prediction for this drug is Classic Stiff Person Syndrome, but this pairing is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale states there is no known mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (inferred from literature within this pack; not confirmed by SAHPRA licensing data — none on file) |
| Predicted New Indication | Classic Stiff Person Syndrome |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for vildagliptin is not available in this evidence pack (flagged as a High-severity data gap). Based on literature captured elsewhere in this pack, vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that raises endogenous GLP-1/GIP levels to improve glycemic control in type 2 diabetes, primarily by enhancing pancreatic islet (alpha and beta cell) function.
Classic Stiff Person Syndrome, by contrast, is a rare autoimmune neurological disorder driven by anti-GAD65 antibodies and disrupted GABAergic transmission. As the model’s own repurposing rationale explicitly states, there is no known mechanistic overlap between the DPP-4/incretin pathway and GABAergic/autoimmune neurological pathways.
This prediction should therefore be read as a pure graph-embedding association from TxGNN, not a mechanistically or clinically supported hypothesis. The high similarity score reflects pattern-matching within the knowledge graph rather than any biological or empirical signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Vildagliptin currently holds no SAHPRA registrations and is not marketed in South Africa (0 licenses on file in this evidence pack).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: A blocking data gap exists — TFDA/SAHPRA label warnings and contraindications have not yet been retrieved, which prevents this candidate from entering the S1 safety pre-assessment stage.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but there is zero clinical trial or literature support, and the model’s own rationale confirms no established mechanistic link between DPP-4 inhibition and stiff person syndrome’s autoimmune/GABAergic pathology. Combined with the absence of SAHPRA registration and missing safety/label data, this candidate does not meet the threshold to proceed.
To proceed, the following is needed:
- Vildagliptin’s SAHPRA-approved Professional Information (warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism of action data from DrugBank — currently a High-severity data gap
- Any emerging preclinical or case-level evidence linking DPP-4 inhibition to autoimmune neurological disease before further evaluation
- Alternative predicted indications in this evidence pack should be considered instead: notably Type 1 Diabetes Mellitus (rank 10) has an L2 evidence level with 50 clinical trials and 20 publications, including a completed RCT on β-cell function (rapamycin + vildagliptin), and is flagged “Research Question” rather than “Hold” — a substantially stronger starting point for further review.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.